KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.90 USD
-0.16 (-2.64%)
Updated Aug 28, 2024 01:57 PM ET
After-Market: $5.96 +0.06 (1.02%) 7:18 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 1 - 20 ( 367 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results Reported; Reiterate Buy; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
2023 Financial Results Reported; Reiterate Buy; Adjusting PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KALA 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Financial Results Reported; Reiterate Buy; Adjusting PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Topline Data from CHASE Ph2b of KPI-012/PCED Expected in H2:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q2:23 Financials; All Eyes on Topline Ph2b CHASE Readout for KPI-012 in Q2:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Ph2b KPI-012/PCED Trial Progresses to Cohort 2, Topline Data in Q1:24; Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results Reported; Reiterate Buy; Raising PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
$15M Grant Awarded to Advance the PCED Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Fast Track Designation Granted For PCED Trial; Reiterate Buy; Raising PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
PCED Trial Reports Positive Safety Data From Cohort 1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Full-Year 2022 Financial Results Reported; Reiterate Buy; Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Ph2b Trial for KPI-012/PCED, Readout in Q1:24; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
IND Accepted for KPI-012/PCED; Runway to Cover Ph2b Readout in Q1:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
IND Application Accepted for KPI-012 in PCED; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y